Home Alzheimer’s Disease Immune Checkpoint Inhibitors May Be Associated with High Activity in MSI-H Cancers

Immune Checkpoint Inhibitors May Be Associated with High Activity in MSI-H Cancers

A meta-analysis of patients with pretreated microsatellite instability-high (MSI-H) cancers treated with immune checkpoint inhibitors (ICIs), published in JAMA Oncology, found that ICIs were correlated with high activity, independent of tumor type and drug used. 

Additionally, the researchers suggested that among molecular biomarkers for selection of treatment, mismatch repair (MMR) proteins may have a predictive value for the activity of immunotherapy.

“Although not currently approved worldwide, according to these findings anti-PD-(L)1 agents represent a potentially important treatment option for (deficient mismatch repair [dMMR]/MSI-H) tumors,” the authors wrote. 

Researchers used published articles that evaluated ICIs in the treatment of advanced MSI-H tumors from inception to December 2019; articles were identified by searching the PubMed, EMBASE, and Cochrane Library…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Podcast Episode Interviewing Brain Cancer Fighter & Survivor : braincancer

Hi all, we have a podcast called Making Headway that is meant as a support for brain injury survivors. My co-host, Eryn, and I...

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Recent Comments